Challenging Treatment Paradigms in HER2-Low and HER2-Ultralow MBC: Experts Examine The Evidence to Guide Individualized Clinical Decisions

Experts insight on caring for patients with HER2-low and HER2-ultralow metastatic breast cancer using HER2-targeted therapy based on recent clinical data through an ASCO satellite symposium, a certified on-demand webcast, expert-written ClinicalThought commentaries, and accompanying downloadable slides.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.